2016
DOI: 10.1097/ijg.0000000000000173
|View full text |Cite
|
Sign up to set email alerts
|

Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy

Abstract: Sustained ocular hypertension following the intravitreal administration of antivascular endothelial growth factor agents is a potentially serious side effect that has not been adequately explained. Further investigation is necessary to determine the role of NO in the mediation of this adverse effect.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
27
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(28 citation statements)
references
References 54 publications
(80 reference statements)
0
27
0
1
Order By: Relevance
“…While different studies have confirmed a higher risk for a conversion to OHT and glaucoma [6][7][8][9][10] , the structural effect on the peripapillary RNFL is less well understood [13][14][15][16] .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…While different studies have confirmed a higher risk for a conversion to OHT and glaucoma [6][7][8][9][10] , the structural effect on the peripapillary RNFL is less well understood [13][14][15][16] .…”
Section: Discussionmentioning
confidence: 99%
“…A significant share of patients requires multiple repeated intravitreal injections (IVIs). An IVI of 50 μL anti-VEGF agent can trigger a persistent increase of intraocular pressure (IOP) 3-4 weeks after injection [6][7][8][9][10] . Agard et al [6] showed that 4.6% ( n = 10) of their study IVI patients had an IOP elevation of more than 25 mm Hg and required antiglaucomatous treatment.…”
Section: Introductionmentioning
confidence: 99%
“…A greater volume with the ranibizumab injection should induce a higher degree of SIOH theoretically, and previous studies have also revealed an elevated IOP after anti-angiogenic agent injection. [ 29 ] Still, there are several possible explanations for our successful IOP control in which no significant IOP elevation was revealed in the study group. First, no patients with preexisting glaucoma, which is a prominent risk factors for SIOH, [ 30 , 31 ] were enrolled in our study.…”
Section: Discussionmentioning
confidence: 94%
“…За последнее время было опубликовано множество статей, описывающих появление повышенного офтальмотонуса после интравитреальных инъекций различных анти-VEGF-препаратов: пегаптаниба, ранибизумаба и афлиберцепта [7][8][9][10][11][12][13][14][15][16].…”
Section: Original Articlesunclassified